Find a Doctor

RK
Areas of Expertise

Ragini R. Kudchadkar

The Emory Clinic, Inc
Oncology, Internal Medicine
Female
Practicing approx. 18 years

Bio

Ragini Kudchadkar is an Oncologist and an Internal Medicine specialist in Atlanta, Georgia. She has been an author on 93 peer reviewed articles and participated in 3 clinical trials in the past 15 years. She is licensed to treat patients in FL.

Areas of Expertise

Contact

Atlanta, GA 30322, US

404-778-7525

Latest Research

Latest Advance
Study
  • Condition: Merkel Cell Carcinoma
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Nivolumab
  • Number of Patients: 39
  • Published —
In this study, researchers evaluated the outcomes of administering nivolumab for the treatment of Merkel cell carcinoma.
Latest Advance
Study
  • Condition: Basal Cell Carcinoma
  • Journal: The British journal of dermatology
  • Treatment Used: Sonidegib
  • Number of Patients: 230
  • Published —
This analysis evaluated the safety and effectiveness of sonidegib in patients with advanced basal cell carcinoma.
Latest Advance
Study
  • Condition: Patients With Advanced Merkel Cell Carcinoma(MCC)
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Pembrolizumab as First-Line Therapy
  • Number of Patients: 50
  • Published —
This study assessed response durability and overall survival (OS) in Merkel cell carcinoma (MCC), an aggressive skin cancer.
Latest Advance
Study
  • Condition: Melanoma Metastatic To The Brain
  • Journal: The New England journal of medicine
  • Treatment Used: combined Nivolumab and Ipilimumab
  • Number of Patients: 94
  • Published —
The purpose of the study was to evaluate the efficacy and safety of nivolumab plus ipilimumab in patients with melanoma who had untreated brain metastases
Latest Advance
Study
  • Condition: Patients with Unresectable BRAFV600E-Mutant Melanoma
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Combined BRAF and HSP90 Inhibition
  • Number of Patients: 21
  • Published —
This study investigated vemurafenib (960 mg p.o. b.i.d.) combined with escalating doses of XL888 (30, 45, 90, or 135 mg p.o. twice weekly) in patients with advanced BRAFV600-mutant melanoma.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Radiation, Biological, Procedure
  • Participants: 20
  • Start Date: May 15, 2020
Pilot Study of Neoadjuvant/Adjuvant Cemiplimab for High Risk Cutaneous Squamous Cell Carcinoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Other, Radiation, Biological
  • Participants: 500
  • Start Date: October 1, 2018
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 369
  • Start Date: July 6, 2016
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)

All Publications
View All

Publication
Study
  • Journal: Melanoma research
  • Published —
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
Publication
Study
  • Journal: JAAD case reports
  • Published —
Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma.

Contact

Atlanta, GA 30322, US

404-778-7525

Affiliations

  • Emory University Hospital
  • Emory University Hospital Midtown
  • Saint Joseph's Hospital Of Atlanta, Inc
  • Emory Johns Creek Hospital

Credentials

  • Graduate InstitutionEmory University School Of Medicine
    2003
  • Licenses
    Internal Medicine in FL
  • Board Certifications
    Medical Oncology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.